Myeloma Trial, Recruiting NCT06784167 Sponsor: OHSU Knight Cancer Institute Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT06784167
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign a consent form before any study-related activities begin
  • People who are 18 years of age or older at the time of signing consent
  • People who have a confirmed diagnosis (proven through laboratory testing of tissue or cell samples) of one of the following blood cancers: multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, or primary mediastinal B cell lymphoma — any number of previous treatments is allowed
  • People who have a history of having received vaccines against common vaccine-preventable diseases in the past
  • People whose treating doctor has approved them to receive CAR-T cell therapy, with the preparatory treatment (conditioning) planned to start within the next 90 days
  • People whose treating doctor has approved them to receive re-vaccination against pneumococcal disease (caused by Streptococcus pneumoniae) or tetanus

Who may not be able to join:

  • People who are currently using medications that suppress the immune system, or who have plans to use such medications during the study, if those medications would affect the study results
  • People who have serious uncontrolled health conditions, including but not limited to an active systemic infection, poorly controlled heart failure, unstable chest pain (angina), or mental health or personal circumstances that would make it difficult to follow the study requirements or make participation inadvisable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
OHSU Knight Cancer Institute
Registry
ClinicalTrials.gov
Start date
10 March 2025
Est. completion
11 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Preserved immunity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov